{"filing":{"accession_number":"0001193125-26-297554","cik":"0001671858","ticker":"SPRY","company_name":"ARS Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"d157645d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/d157645d8k.htm"},"events":[{"id":16479,"run_id":14726,"accession_number":"0001193125-26-297554","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the appointment of Donn Casale as Chief Executive Officer effective immediately and his concurrent appointment to the Board as a Class III director. While the section also mentions Richard Lowenthal's termination without cause, the principal disclosed action centers on Casale's elevation to CEO and board appointment, making this an exec_appointment event. This is material as it represents a change in the company's principal executive officer.","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14589,"accession_number":"0001193125-26-297554","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Donn Casale as Chief Executive Officer effective immediately and his concurrent appointment to the Board as a Class III director. While the section also mentions Richard Lowenthal's termination without cause, the principal disclosed action centers on Casale's elevation to CEO and board appointment, making this an exec_appointment event. This is material as it represents a change in the company's principal executive officer.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:40:06.116928+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14589,"accession_number":"0001193125-26-297554","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Donn Casale as Chief Executive Officer effective immediately and his concurrent appointment to the Board as a Class III director. While the section also mentions Richard Lowenthal's termination without cause, the principal disclosed action centers on Casale's elevation to CEO and board appointment, making this an exec_appointment event. This is material as it represents a change in the company's principal executive officer.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:40:06.116928+00:00","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-07-07"}]}